Putnam Investments LLC Blueprint Medicines Corp Transaction History

Putnam Investments LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$49.93 - $77.7 $8.68 Million - $13.5 Million	173,910 New	173,910 $11.5 Million
Q2 2021 Aug 16, 2021	SELL	$82.78 - $101.0 $7.34 Million - $8.96 Million	-88,700 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$90.71 - $108.28 $8.05 Million - $9.6 Million	88,700 New	88,700 $8.62 Million
Q2 2020 Aug 14, 2020	SELL	$57.09 - $79.27 $5.96 Million - $8.28 Million	-104,400 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$48.11 - $82.22 $5.02 Million - $8.58 Million	104,400 New	104,400 $6.11 Million
Q4 2019 Feb 14, 2020	SELL	$66.73 - $82.59 $1.95 Million - $2.42 Million	-29,284 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$72.9 - $101.41 $846,806 - $1.18 Million	-11,616 Reduced 28.4%	29,284 $2.15 Million
Q2 2019 Aug 14, 2019	BUY	$73.54 - $97.8 $3.01 Million - $4 Million	40,900 New	40,900 $3.86 Million

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Putnam Investments LLC, based on Form 13F filings with the SEC.

Stay updated on Putnam Investments LLC with notifications on news.